Becton Dickinson trades at a forward P/E of roughly 13xa 3550% discount to medtech peersdespite owning 60% of the U.S. infusion pump market, generating over 90% of revenue from recurring consumables, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results